πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12214023

Compositions and methods for expressing factor IX

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215131

IgG Fc-IL2-RΞ±-IL2 fusions and methods of use thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215148

Antigen binding molecule formats

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215138

Compositions and methods for internalizing enzymes

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12209238

CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12209180

Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use a

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12202883

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12201673

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12186378

Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12187772

IL10 agonists and methods of use thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12187792

IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180272

Antigen binding molecule formats

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12168036

Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion prot

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12169199

Activity based host cell protein profiling

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12168681

Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12163192

Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12161097

Non-human animals having a humanized signal-regulatory protein gene

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12162943

High affinity human antibodies to human IL-4 receptor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12157758

Readily isolated bispecific antibodies with native immunoglobulin format

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12157891

Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12152067

Human antibodies to ebola virus glycoprotein

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12150959

Chimeric antigen receptors with BCMA specificity and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144864

Tubulysins and protein-tubulysin conjugates

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12139546

Methods of treating urea cycle disorders by interfering with glucagon receptor signaling

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted